The CCR5 antagonist Leronlimab, a humanized monoclonal PRO 140 γ4-chain antibody (PRO 140), has already entered in a phase 2 randomized clinical trial for COVID-19 patients with mild-to-moderate symptoms (20). The gene discussed is CCR5; the disease is COVID-19.